TY - JOUR
T1 - The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
AU - Geisler, Christian H
AU - Kolstad, Arne
AU - Laurell, Anna
AU - Räty, Riikka
AU - Jerkeman, Mats
AU - Eriksson, Mikael
AU - Nordström, Marie
AU - Kimby, Eva
AU - Boesen, Anne Marie
AU - Nilsson-Ehle, Herman
AU - Kuittinen, Outi
AU - Lauritzsen, Grete F
AU - Ralfkiaer, Elisabeth
AU - Ehinger, Mats
AU - Sundström, Christer
AU - Delabie, Jan
AU - Karjalainen-Lindsberg, Marja-Liisa
AU - Brown, Peter
AU - Elonen, Erkki
AU - Nordic Lymphoma Group
PY - 2010/2/25
Y1 - 2010/2/25
N2 - Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P <.001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPI(B) (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPI(B) is feasible.
AB - Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P <.001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPI(B) (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPI(B) is feasible.
U2 - http://dx.doi.org/10.1182/blood-2009-08-236570
DO - http://dx.doi.org/10.1182/blood-2009-08-236570
M3 - Journal article
VL - 115
SP - 1530
EP - 1533
JO - Blood
JF - Blood
SN - 0006-4971
IS - 8
ER -